Soft tissue and bone sarcomas disproportionately affect children, adolescents, and young adults. Although considered a rare disease, sarcomas continue to have a devastating effect on these patients and their loved ones, and their impact on our society far exceed their relatively low prevalence. Because of its rarity and heterogeneity, clinical decision making on management of sarcomas are often individualized and without a consensus treatment strategy. Furthermore, research to improve clinical outcomes are particularly challenging as sizeable studies are hard to produce. By improving our knowledge about the molecular biology of sarcomas, we hope to identify new treatment strategies and targets for further drug development. In this Special Issue in Soft Tissue and Bone Sarcomas, we invited manuscripts that sought to elucidate the pathophysiology and carcinogenesis of soft tissue and bone sarcomas and identify new arenas for sarcoma research. We were particularly interested in manuscripts deciphering the mechanisms of putative targets for sarcoma treatments. By devoting a special issue solely on soft tissue and bone sarcomas, we hoped to display and bridge a critical mass of new and exciting research that can lead the way to improving cancer care for this cohort of patients. The breadth and quality of manuscripts submitted for our review far exceeded our expectations. We were able to include review articles as well as primary research manuscripts. Our papers encompass studies of clinical, translational, and basic science. We included studies describing investigations of sarcomas in vitro as well as in vivo, in dogs as well as in humans, systemic treatments as well as radiation therapies, and a det ailed description of a clinical trial as well as an overview of multiple clinical trials. The richness of articles that we were able to publish in this collection underlies the growing enthusiasm to study, collaborate, and take scientific risks in studying sarcomas. We were often told that our field is too rare, too heterogeneous, or too far from the mainstream cancer conversation that our research is not worth funding, publishing, or publicizing, but times are changing. I feel that, as a community of scientists, sarcoma investigators have finally reached the critical mass required in all disciplines to raise the level of research to that elusive next level.